Peptides for libido: PT-141 and the labs worth checking first
Low libido is a symptom with a long list of measurable causes, and most of them are not addressed by a peptide.
Key takeaways
- PT-141 acts on arousal pathways in the nervous system rather than on blood flow, which is why it is studied in women as well as men.
- Testosterone, SHBG, estradiol, thyroid function, prolactin, and ferritin explain a large share of low libido cases.
- SSRIs, beta blockers, and finasteride are common medication contributors and are reviewed before anything is added.
- Nausea is the most commonly reported effect and the usual reason someone discontinues.
PT-141, also called bremelanotide, acts on arousal pathways in the nervous system rather than on blood flow, which is why it is studied in women as well as men.
Before that conversation is useful, there is a panel worth running: total and free testosterone, SHBG, estradiol, thyroid function, prolactin, ferritin, and a review of current medications. SSRIs, beta blockers, and finasteride are common contributors.
If the panel explains the symptom, treating the panel is the better plan. If it does not, PT-141 becomes a reasonable thing to discuss with the prescribing provider.
Low libido is a symptom, not a diagnosis
It is also one of the most measurable symptoms in men's and women's health, which is why starting with a panel is not a stalling tactic.
Sleep debt, chronic stress, relationship context, and depression all sit alongside the lab work, and none of them are corrected by a prescription. An honest consult says so.
The panel worth running first
These are the values that most often explain the complaint on their own.
- Total and free testosterone, with SHBG, because a normal total with high SHBG can leave free testosterone low.
- Estradiol, in both men and women.
- Thyroid function, which affects energy and libido together.
- Prolactin, where an elevated value has its own workup.
- Ferritin and iron, especially in women with heavy periods.
- Fasting insulin and HbA1c, since metabolic health and sexual function track together.
- A medication review: SSRIs, beta blockers, finasteride, and some oral contraceptives are frequent contributors.
Where PT-141 fits, and what it does not do
PT-141, also called bremelanotide, acts on melanocortin pathways involved in arousal. That is a different mechanism from sildenafil and tadalafil, which work on blood flow, and it is why PT-141 is sometimes considered when a blood flow medication did not address the actual complaint. PT-141 is FDA approved for premenopausal women with hypoactive sexual desire disorder, and even in those trials the average benefit was modest, which is worth knowing before it is considered off that indication.
Reported effects include nausea, flushing, headache, and a temporary rise in blood pressure with a small drop in heart rate. It is not appropriate with uncontrolled high blood pressure or known cardiovascular disease. Some people notice temporary darkening of skin or existing moles with repeated use, because the pathway overlaps with pigmentation.
How Baseline approaches it
We recommend running the panel first, and an independent licensed provider decides what, if anything, the results support. If low free testosterone or an untreated thyroid problem is the driver, that is the plan, and it is usually the more durable one.
PT-141 is documented here for education and is not currently available to order through Baseline. Where it is appropriate, an independent licensed provider makes that decision and reviews use at check-ins rather than leaving it open-ended.
What this means for you
Run the panel before adding anything. A large share of low libido is explained by testosterone, SHBG, thyroid, prolactin, iron, or a medication you are already taking, and those are more durable to fix.
Therapies discussed here
References
- Therapies: PT-141
- Biomarker hub: Hormonal biomarkers
- Focus areas: Hormonal Health